Personalis, Inc.
Personalis, Inc. (PSNL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PSNL · as of Jun 8, 2026
Key Statistics
Explore Personalis, Inc. Data
psnl stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 91.7%
The PSNL analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $11.00, representing +9.56% upside from the current price of $10.04.
Competitors & Peers
psnl competitorsPSNL
BFLY
CDNA
CSTL
EVH
FLGTStock Performance
Full HistoryAbout Personalis, Inc.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer …
what is personalis, inc. · psnl stock overview · personalis, inc. company profile · who is personalis, inc. ceo · psnl NASDAQ · personalis, inc. headquarters · personalis, inc. business segments
About Stock Overview & Key Data
Personalis, Inc. (PSNL) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Jun 20, 2019. As of the latest trading session, PSNL stock price is $10.04, with a market capitalization of $891.6M. The stock has returned +92.22% over the past 12 months and +30.40% year-to-date.
According to 12 Wall Street analysts, the consensus rating for Personalis, Inc. stock is Buy, with an average 12-month price target of $11.00. In fiscal year 2025, Personalis, Inc. reported revenue of — and net income of -$81.3M. For detailed data — including Personalis, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Personalis, Inc. (PSNL) stock price is $10.04. The stock is traded on NASDAQ under the ticker symbol PSNL. The 52-week range is $3.84 – $11.85.